This study aims to provide evidence regarding whether Qingufei paidu decoction(清肺排毒汤,QFPD)treatment in the acute phase shows long-term benefits for coronavirus disease 2019-associated sequelae.The 10 databases wi...This study aims to provide evidence regarding whether Qingufei paidu decoction(清肺排毒汤,QFPD)treatment in the acute phase shows long-term benefits for coronavirus disease 2019-associated sequelae.The 10 databases will be retrieved.Every reference list of related trials and gray literature will be searched as well.Study screening,data extraction,and risk of bias evaluation will be performed by two reviewers(CUI Hanjin and FAN Rong).Data analysis will be conducted by using STATA(version 14).Statistical heterogeneity will be explored by a standardχ2 test with a significance level of P<0.10.Funnel plots,Egger’s&Begg’s test,and Trim and Fill analysis will be used for publication bias assessment.The results of the present Meta-analysis and systematic review will be disseminated via peer-review journal publication.Ethical approval is not required,as this Meta-analysis will not contain any individual patient data.This systematic review has been registered on PROSPERO(registration number:CRD42021246937)on 15 April 2021.展开更多
This work is aimed to study the therapeutics and pharmacology of the treatment of severe acute respiratory infection caused by coronavirus disease-19 (COVID-19) with traditional Chinese medicine (TCM) “Qingfei Paidu ...This work is aimed to study the therapeutics and pharmacology of the treatment of severe acute respiratory infection caused by coronavirus disease-19 (COVID-19) with traditional Chinese medicine (TCM) “Qingfei Paidu Decoction”. We analyze the “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia” (Version I to Version VII) made by China, “Clinical management of severe acute respiratory infection when novel coronavirus <span style="font-family:Verdana;">(2019-nCoV) infection is suspected—Interim guidance” made by World Healt</span><span style="font-family:Verdana;">h Organization (WHO), “Therapeutic Guidelines: Respiratory” published by Australia, and the origin of classical prescription of Qingfei Paidu Decoction: “Shanghan Lun (Treatise on Febrile Diseases)” and “Jinkui Yaolue (Synopsis of Golden Chamber)”. We search the dictionary of traditional Chinese medicine (Version II) manually. We search literatures from 2001 to 2020 on Wiley online library. We conduct a comparative study on the therapeutic options and indications among Qingfei Paidu Decoction, COVID-19 and chronic obstructive pulmonary disease (COPD). And we carry out pharmacological inquiry of Qingfei Paidu Decoction. The therapeutic options and indications of Qingfei Paidu Decoction in China, COVID-19 and COPD are considered to be basically consistent. Qingfei Paidu Decoction has a definite therapeutic effect on the symptoms, basic diseases and complications for COVID-19 and COPD. Qingfei Paidu Decoction is a possible choice of </span><span style="font-family:Verdana;">phytotherapy </span><span style="font-family:Verdana;">for severe acute respiratory infection caused by COVID-19.</span>展开更多
The coronavirus disease 2019(COVID-19)was a newly discovered infectious respiratory disease and characterized by wide prevalence,high incidence rate and fast progress and dangerous,which belonged to the category of&qu...The coronavirus disease 2019(COVID-19)was a newly discovered infectious respiratory disease and characterized by wide prevalence,high incidence rate and fast progress and dangerous,which belonged to the category of"cold-wet plague"in TCM.The onset of COVID-19 was caused by pestilence,which mingled with seasonal cold-dampness and invaded the human body when external defensive qi was weak and then leaded to the accumulation of Yang qi.Different from exogenous pathogenic factors transmitted from the external to the internal or followed the transmission law of Wei,Qi,Ying and Xue,the nature of pestilence belonged to the category of pathogenic fire,spreading as soon as possible,from the external to the internal and from the upper and lower part of triple energizer,even to every part.At the very beginning,the pestilence attacked from the Taiyang meridian into the Yangming meridian quickly,or straight into the three Yang meridian,which was called"triple-yang combination of diseases".Manifestations of fever,aversion to cold and pain of body were conformed to the exterior syndrome of Taiyang,as well as manifestations of fullness and discomfort in chest,vomiting and spitting and diarrhea were conformed to the syndrome of half-interior-half-exterior;And symptoms manifested as high fever,faint,and abdominal fullness and constipation were conformed to the syndrome of Yangming;But sometimes,there was cold-dampness surrounding the exterior at the beginning along with intense interior pathogenic fire.Or at the beginning,the exterior factors invaded into three Yin meridians quickly while have not been eliminated,which may lead to the syndrome of inner blocking causing collapse or Jue exhaustion.The most typical syndrome of COVID-19 was triple-yang combination of diseases,which was often seen in mild,moderate and part of severe cases.Hence"Qingfei Paidu Decoction"was prescribed especially for this kind of syndrome.Its accurate efficacy has been proved by that mild cases converting to severe cases in the mobile cabin hospital have been effectively restrained and thus the progression of the disease has blocked.Composition analysis showed that Mahuang decoction with Maxing Shigan decoction was to relieve exterior Taiyang syndrome,Xiaochaihu decoction was for harmonizing half-superficies and half-interior Shaoyang syndrome,and large dose of gypsum was used to clear interior heat of the Yangming meridian,and Shegan Mahuang decoction and Xiaoqinglong plus gypsum decoction was for lowering the adverse qi and resolving fluid,and Wuling San was for warming the triple energizer and transforming qi and draining water."Qingfei Paidu Decoction"was an syncretic innovation of classical prescriptions from Treatise on Febrile Diseases,which was not made up of herbs but multiple concordant prescriptions helping to get twice the result with half the effort,so that the"cold-wet plague"can be quickly discharged.展开更多
目的:构建中草药来源的目标微小RNA(microRNA,miR)在小鼠肺组织中的靶基因谱检测方法,利用该方法检测清肺排毒汤所含miR-320—靶基因谱及其生物学功能,为清肺排毒汤治疗病毒性肺炎的分子机制补充miR维度的数据支撑。方法:采用二代高通...目的:构建中草药来源的目标微小RNA(microRNA,miR)在小鼠肺组织中的靶基因谱检测方法,利用该方法检测清肺排毒汤所含miR-320—靶基因谱及其生物学功能,为清肺排毒汤治疗病毒性肺炎的分子机制补充miR维度的数据支撑。方法:采用二代高通量测序测定目标miR(miR-320)在清肺排毒汤中的表达情况,利用“结合态miR—靶基因抓取测序技术(capturing and sequencing of miRNA-target complex technology,CSCT)”初步检测其在小鼠肺组织中的靶基因谱,并采用Alphafold3验证检测结果,取其交集作为目标miR的靶基因谱;进而分析靶基因谱的功能,阐释清肺排毒汤通过miR-320在小鼠肺组织中的调控功能;此外,将检测结果与TargetScan的预测结果进行比对,验证本检测方法(CSCT+Alphafold3序贯检测法)的优势。结果:高通量测序结果表明清肺排毒汤中富含miR-320,其表达含量居前50位。miR-320在小鼠肺组织中可作用于26类靶基因,其中19类为已知基因(18类为mRNA以及1类为转录增强子),其主要通过miR经典作用模式识别靶基因,与26类靶基因具有良好的碱基互补性,最小自由能在-35.8~-21.8 kcal·mol^(-1)之间;Alphafold3预测的靶基因的iPTM和PTM之和最小值为1.1,位于高置信度区域,100%验证了CSCT的检测结果,据此确证26类靶基因为miR-320作用谱;与TargetScan相比,本研究构建的“CSCT+Alphafold3序贯检测法”对于靶基因谱的检测准确率更高。这些靶基因具有多种功能,主要富集于白介素介导的免疫信号通路,在抗原处理与提呈、免疫因子或细胞介导的细胞凋亡、淋巴细胞增殖与活化等生物学过程中发挥作用。结论:清肺排毒汤所含miR-320在小鼠肺组织内主要富集于免疫调节相关通路,这可能是清肺排毒汤治疗病毒性肺炎的miR分子机制之一;本研究构建的“CSCT+Alphafold3”法对于miR靶基因谱的检测具有较高的可靠性和准确性,可作为中药汤剂中miR—靶基因互作谱检测技术。展开更多
文摘This study aims to provide evidence regarding whether Qingufei paidu decoction(清肺排毒汤,QFPD)treatment in the acute phase shows long-term benefits for coronavirus disease 2019-associated sequelae.The 10 databases will be retrieved.Every reference list of related trials and gray literature will be searched as well.Study screening,data extraction,and risk of bias evaluation will be performed by two reviewers(CUI Hanjin and FAN Rong).Data analysis will be conducted by using STATA(version 14).Statistical heterogeneity will be explored by a standardχ2 test with a significance level of P<0.10.Funnel plots,Egger’s&Begg’s test,and Trim and Fill analysis will be used for publication bias assessment.The results of the present Meta-analysis and systematic review will be disseminated via peer-review journal publication.Ethical approval is not required,as this Meta-analysis will not contain any individual patient data.This systematic review has been registered on PROSPERO(registration number:CRD42021246937)on 15 April 2021.
文摘This work is aimed to study the therapeutics and pharmacology of the treatment of severe acute respiratory infection caused by coronavirus disease-19 (COVID-19) with traditional Chinese medicine (TCM) “Qingfei Paidu Decoction”. We analyze the “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia” (Version I to Version VII) made by China, “Clinical management of severe acute respiratory infection when novel coronavirus <span style="font-family:Verdana;">(2019-nCoV) infection is suspected—Interim guidance” made by World Healt</span><span style="font-family:Verdana;">h Organization (WHO), “Therapeutic Guidelines: Respiratory” published by Australia, and the origin of classical prescription of Qingfei Paidu Decoction: “Shanghan Lun (Treatise on Febrile Diseases)” and “Jinkui Yaolue (Synopsis of Golden Chamber)”. We search the dictionary of traditional Chinese medicine (Version II) manually. We search literatures from 2001 to 2020 on Wiley online library. We conduct a comparative study on the therapeutic options and indications among Qingfei Paidu Decoction, COVID-19 and chronic obstructive pulmonary disease (COPD). And we carry out pharmacological inquiry of Qingfei Paidu Decoction. The therapeutic options and indications of Qingfei Paidu Decoction in China, COVID-19 and COPD are considered to be basically consistent. Qingfei Paidu Decoction has a definite therapeutic effect on the symptoms, basic diseases and complications for COVID-19 and COPD. Qingfei Paidu Decoction is a possible choice of </span><span style="font-family:Verdana;">phytotherapy </span><span style="font-family:Verdana;">for severe acute respiratory infection caused by COVID-19.</span>
基金National Natural Science Foundation of China(No.81473592)Changchun University of Traditional Chinese Medicine graduate student“JuJing Cup”academic research and innovation project(No.FK201922).
文摘The coronavirus disease 2019(COVID-19)was a newly discovered infectious respiratory disease and characterized by wide prevalence,high incidence rate and fast progress and dangerous,which belonged to the category of"cold-wet plague"in TCM.The onset of COVID-19 was caused by pestilence,which mingled with seasonal cold-dampness and invaded the human body when external defensive qi was weak and then leaded to the accumulation of Yang qi.Different from exogenous pathogenic factors transmitted from the external to the internal or followed the transmission law of Wei,Qi,Ying and Xue,the nature of pestilence belonged to the category of pathogenic fire,spreading as soon as possible,from the external to the internal and from the upper and lower part of triple energizer,even to every part.At the very beginning,the pestilence attacked from the Taiyang meridian into the Yangming meridian quickly,or straight into the three Yang meridian,which was called"triple-yang combination of diseases".Manifestations of fever,aversion to cold and pain of body were conformed to the exterior syndrome of Taiyang,as well as manifestations of fullness and discomfort in chest,vomiting and spitting and diarrhea were conformed to the syndrome of half-interior-half-exterior;And symptoms manifested as high fever,faint,and abdominal fullness and constipation were conformed to the syndrome of Yangming;But sometimes,there was cold-dampness surrounding the exterior at the beginning along with intense interior pathogenic fire.Or at the beginning,the exterior factors invaded into three Yin meridians quickly while have not been eliminated,which may lead to the syndrome of inner blocking causing collapse or Jue exhaustion.The most typical syndrome of COVID-19 was triple-yang combination of diseases,which was often seen in mild,moderate and part of severe cases.Hence"Qingfei Paidu Decoction"was prescribed especially for this kind of syndrome.Its accurate efficacy has been proved by that mild cases converting to severe cases in the mobile cabin hospital have been effectively restrained and thus the progression of the disease has blocked.Composition analysis showed that Mahuang decoction with Maxing Shigan decoction was to relieve exterior Taiyang syndrome,Xiaochaihu decoction was for harmonizing half-superficies and half-interior Shaoyang syndrome,and large dose of gypsum was used to clear interior heat of the Yangming meridian,and Shegan Mahuang decoction and Xiaoqinglong plus gypsum decoction was for lowering the adverse qi and resolving fluid,and Wuling San was for warming the triple energizer and transforming qi and draining water."Qingfei Paidu Decoction"was an syncretic innovation of classical prescriptions from Treatise on Febrile Diseases,which was not made up of herbs but multiple concordant prescriptions helping to get twice the result with half the effort,so that the"cold-wet plague"can be quickly discharged.
文摘目的:构建中草药来源的目标微小RNA(microRNA,miR)在小鼠肺组织中的靶基因谱检测方法,利用该方法检测清肺排毒汤所含miR-320—靶基因谱及其生物学功能,为清肺排毒汤治疗病毒性肺炎的分子机制补充miR维度的数据支撑。方法:采用二代高通量测序测定目标miR(miR-320)在清肺排毒汤中的表达情况,利用“结合态miR—靶基因抓取测序技术(capturing and sequencing of miRNA-target complex technology,CSCT)”初步检测其在小鼠肺组织中的靶基因谱,并采用Alphafold3验证检测结果,取其交集作为目标miR的靶基因谱;进而分析靶基因谱的功能,阐释清肺排毒汤通过miR-320在小鼠肺组织中的调控功能;此外,将检测结果与TargetScan的预测结果进行比对,验证本检测方法(CSCT+Alphafold3序贯检测法)的优势。结果:高通量测序结果表明清肺排毒汤中富含miR-320,其表达含量居前50位。miR-320在小鼠肺组织中可作用于26类靶基因,其中19类为已知基因(18类为mRNA以及1类为转录增强子),其主要通过miR经典作用模式识别靶基因,与26类靶基因具有良好的碱基互补性,最小自由能在-35.8~-21.8 kcal·mol^(-1)之间;Alphafold3预测的靶基因的iPTM和PTM之和最小值为1.1,位于高置信度区域,100%验证了CSCT的检测结果,据此确证26类靶基因为miR-320作用谱;与TargetScan相比,本研究构建的“CSCT+Alphafold3序贯检测法”对于靶基因谱的检测准确率更高。这些靶基因具有多种功能,主要富集于白介素介导的免疫信号通路,在抗原处理与提呈、免疫因子或细胞介导的细胞凋亡、淋巴细胞增殖与活化等生物学过程中发挥作用。结论:清肺排毒汤所含miR-320在小鼠肺组织内主要富集于免疫调节相关通路,这可能是清肺排毒汤治疗病毒性肺炎的miR分子机制之一;本研究构建的“CSCT+Alphafold3”法对于miR靶基因谱的检测具有较高的可靠性和准确性,可作为中药汤剂中miR—靶基因互作谱检测技术。
